PLAINSBORO, N.J., July 10, 2019 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release second quarter 2019 financial results on Wednesday, July 24, 2019, prior to market open.

PLAINSBORO, N.J., June 24, 2019 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today announced the promotion of Glenn Coleman to the newly-created role of chief operating officer (COO) and appointed Carrie Anderson as chief

PLAINSBORO, N.J., May 23, 2019 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will present at the following healthcare conferences in June: On Wednesday, June 5, 2019 at 4:30 p.m.

PLAINSBORO, N.J., April 30, 2019 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will present at the following healthcare conference in May: On Tuesday, May 14, 2019 at 4:20 p.m.

Reported revenues amounted to $359.7 million; organic revenues increased 3.1%  GAAP and adjusted earnings per diluted share were $0.38 and $0.65, respectively The Company reaffirms reported and organic revenue guidance for the full-year 2019 PLAINSBORO, N.J., April 24, 2019 (GLOBE NEWSWIRE) --

New innovations designed to help advance patient care PLAINSBORO, N.J., April 11, 2019 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, announced today that it will feature its latest innovations at the American Association

PLAINSBORO, N.J., April 09, 2019 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release first quarter 2019 financial results on Wednesday, April 24, 2019, prior to market open.

PLAINSBORO, N.J. and TOKYO, March 14, 2019 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART ), a global leader in medical technology, announces the recent approval of DuraGen ® Dural Regeneration Matrix in Japan. DuraGen is the first and only non-autologous collagen

PLAINSBORO, N.J., March 07, 2019 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will present at the following healthcare conference in March: On Tuesday, March 19, 2019 at 8:00 a.m.

Fourth Quarter 2018 reported revenue increased 4.0% to $383.3 million; organic revenue increased 4.4% Fourth Quarter 2018 GAAP earnings per diluted share were $0.29; adjusted earnings per diluted share were $0.65 The Company provides financial guidance for 2019 including total revenue in the range

PLAINSBORO, N.J., Feb. 13, 2019 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced the launch of the Integra® Panta® 2 TTC Arthrodesis Nail System for tibio-talo-calcaneal (TTC) fusion of the ankle due to severe

PLAINSBORO, N.J., Jan. 31, 2019 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release fourth quarter and full-year 2018 financial results on Thursday, February 21, 2019, prior to market open.

PLAINSBORO, N.J. , Jan. 10, 2019 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation  (Nasdaq:IART), a leading global medical technology company, today announced the full market release of the Integra® Titan™ Reverse Shoulder System-S (RSS-S).  This launch includes a new glenoid baseplate

PLAINSBORO, N.J., Jan. 09, 2019 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation  (Nasdaq:IART), a leading global medical technology company, today announced the appointment of Rhonda Germany Ballintyn to its board of directors, effective today.  Ms.

PLAINSBORO, N.J., Jan. 08, 2019 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation  (Nasdaq: IART ), a leading global medical technology company, today announced it has signed a license and development agreement with Consortium of Focused Orthopedists, LLC (CFO), for a short stem and